What's happening
This bill requires drug manufacturers to notify the attorney general of deals that delay generic drugs, with penalties for noncompliance.
Why it matters
Increases transparency around “pay-for-delay” deals. By requiring drug manufacturers to disclose agreements that delay generics, the bill brings to light practices that may keep drug prices higher for longer, allowing for increased oversight and public awareness.
Empowers state health and insurance stakeholders. The attorney general must share this information with Medicaid, managed care plans, health carriers, and pharmacy benefit managers, potentially enabling these entities to better negotiate drug pricing, monitor anticompetitive behavior, and plan formularies.
Creates a public, searchable database. The bill mandates that disclosed agreements be posted online by the attorney general in a searchable format, increasing public access to information about drug costs, manufacturers, and diseases affected by these deals—potentially aiding advocacy and consumer choice.
Imposes financial penalties for noncompliance. Substantial daily fines for manufacturers who fail to report qualifying deals provide a strong deterrent against nondisclosure, potentially reducing the frequency of undisclosed arrangements that could harm consumers.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Expose Delays for Cheaper Drugs
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to consumer affairs and protection
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Require Drug Deal Transparency
In Senate Committee · Consumer Protection · Sponsor Alessandra Biaggi
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
8824
IN ASSEMBLY
January 12, 2022
Introduced by M. of A. GALLAGHER -- read once and referred to the Committee on Consumer Affairs and Protection
AN ACT to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. This act shall be known and may be cited as the "manufacturer disclosure and transparency act".
§ 2. The general business law is amended by adding a new section 396- rrr to read as follows:
§ 396-rrr. Delay of introduction of generic medications. 1. (a) Each pharmaceutical manufacturer doing business in this state that manufactures a brand name prescription drug and enters into an arrangement, through agreement or otherwise, with another pharmaceutical manufacturer that has the purpose or effect of delaying or preventing such other manufacturer from introducing a generic substitute for such drug into the marketplace shall, not later than thirty days after entering into such arrangement, send notice to the attorney general, in a form and manner prescribed by the attorney general, disclosing the name of such drug, the wholesale price, the disease such drug is commonly prescribed to treat, the manufacturer of such drug, the name of the generic manufacturer, and the length of the delay.
(b) The attorney general shall, no later than thirty days after receiving a notice pursuant to paragraph (a) of this subdivision, share the information with the drug utilization review board established under section three hundred sixty-nine-bb of the social services law, all medicaid managed care plans, health carriers and pharmacy benefits managers doing business in the state in a format and manner prescribed by the attorney general.
2. The office of the attorney general shall post on its website all the notices required pursuant to paragraph (a) of subdivision one of this section in a format and manner developed by the attorney general
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD02926-01-1
that is searchable by drug, cost, disease, and manufacturer both for the brand and generic drug for public review.
3. For a violation by a manufacturer of a brand name drug who knowingly or negligently fails to notify the attorney general as required in paragraph (a) of subdivision one of this section, the attorney general shall fine such manufacturer no less than five thousand dollars for the first violation for each day such manufacturer fails to properly notify the attorney general pursuant to the requirements of this section and no less than ten thousand dollars for each violation thereafter for each day such manufacturer fails to properly notify the attorney general pursuant to the requirements of this section.
4. The attorney general is authorized to promulgate rules and regulations necessary for the implementation of this section.
§ 3. This act shall take effect on the one hundred eightieth day after it shall have become a law.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.